Botulinum Toxin – The New Paradigm A Review Articl
Botulinum Toxin – The New Paradigm
DOI:
https://doi.org/10.70284/njirm.v5i3.749Keywords:
Botulinum toxin - A, Botulinum toxin – B, neurotransmitter releaseAbstract
Application of Botulinum toxin-A (Botox) in the field of dentistry is a new and upcoming. It acts by preventing the release of Acetylcholine at neuromuscular junction, which inhibits the contraction of muscles. This blockade is temporary, inhibiting the masticatory efficiency and function. It will return to its original levels once the effect of Botox has subsided, varying from three to four months. Botox is a viable treatment for many facial, TMD and oral dysfunctions when they are musculature based. Using Botox requires minimal training for a general dentist. It is most appropriate in patients who are refractory to other treatments.[Shah S NJIRM 2014; 5(3):126-132]
References
1. Blumenfeld A. Botulinum toxin type A in the treatment of Dental conditions. Inside Dent 2007;2:1-5.
2. US Food and Drug Administration. Early Communication about an Ongoing Safety Review of Botox and Botox Cosmetic (Botulinum toxin
Type A) and Myobloc (Botulinum toxin TypeB). February 2008.-[accessed12October2010] Availablefrom:http:/www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm070366.htm
3. US Food and Drug Administration (United States). Early Communication about an Ongoing Safety Review of Botox and Botox Cosmetic (Botulinum toxin Type A) and Myobloc (Botulinum toxin Type B).April,2009.-[accessed 1 December 2010] Availablefrom:http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm070366.htm
4. US Food and Drug Administration. Information for Healthcare Professionals: OnabotulinumtoxinA (marketed as Botox/Botox Cosmetic), AbobotulinumtoxinA (marketed as Dysport) and RimabotulinumtoxinB (marketed as Myobloc). August,2009.-[accessed 1 December2010]Availablefrom:www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforhealthcareprofessionals/ucm174949.htm
5. Katz H.Botulinum Toxins in Dentistry-The New Paradigm for Masticatory Muscle Hypertonicity. Singapore Dent J 2005;27:7–12
6. BOTOX (onabotulinumtoxinA) for injection, for intramuscular, intradetrusor, or intradermal use.InitialU.S.Approval:1989Availablefrom:http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=33d066a9-34ff-4a1a-b38b-d10983df3300 7. Rao, L. B., Sangur, R., & Pradeep, S. Application of Botulinum toxin Type A: An arsenal in dentistry.IJDR2011;22:440-5.
8. Brashear A. The botulinum toxins in the treatment of cervical dystonia. SeminNeurol 2001;21:85–90.
9. Ihde S. Prophylactic use of botulinum toxin in dental implantlogy. Cranio‑maxillofacial Implant Dir2007;2:3‑8. 10. Kumar, P., Khattar, A., Goel, R., & Kumar, A. Role of Botox in Efficient Muscle Relaxation and Treatment Outcome: An Overview.Annals of medical and health sciences research2013;3:131.
11. Glaros AG, Tabacchi KN, Glass EG. Effect of parafunctional clenching on TMD pain and hearing loss. J Orofac Pain 1998; 12:145–52.12. Malcmacher L. "Botulinum Toxin (Botox and Dysport) Use for Dental and Facial Pain Treatment."American Academy of Facial Esthetics. [accessed 2012 January]Availablefrom:http:/www.facialesthetics.org/esthetics/articles/botulinum_toxin_botox_and_dysport_use_for_dental_and_facial_pain_treatment.
13. Borodic GE, Acquadro MA. The use of botulinum toxin for the treatment of chronic facial pain. J Pain 2002;3:21- 27.
14. Naumann M, Albanese A, Heinen F, Molenaers G, Relja M. Safety and efficacy of Botulinum toxin type A follow- ing long-term use. Eur J Neurol 13 (suppl) 2006;4:35-40.
15. Song PC, Schwartz J, Blitzer A. The emerging role of botulinum toxin in the treatment of temporomandibular disorders [reviews]. Oral Dis 2007;13:253-60.
16. Freund B, Schwartz M, Symington JM. The use of botulinum toxin for the treatment of temporomandibular disorders: preliminary findings. J Oral MaxillofacSurg 1999;57:916–20.
17. Kurtoglu C, Gur OH, Kurkcu M, Sertdemir Y, Guler-Uysal F, Uysal H. Effect of botulinum toxin A in myofascial pain patients with or without functional disc displacement. J Oral MaxillofacSurg2008;66:1644-51
18. Silberstein S, Mathew N, Saper J, Jenkins S. Botulinum toxin type A as a migraine preventive treatment. For the BOTOX Migraine Clinical Research Group. Headache 2000;40:445-50.
19. Elcio JP. BOTOX injections relieve severe facial pain.-[last cited 2009]Available from: http://www.news-medical.net/news/2005/10/25/14010.aspx.
20. Lawrence R. BOTOX for Headache: Mechanism of Action. -[last cited 2009]Available from: http://www.headachedrugs.com.Migrainepage.formulation.net/…/botox-for-headache-mechanism-of-action-t 164.htm.
21. Tan EK, Jankovic J. Treating severe bruxism with botulinum toxin. J Am Dent Assoc 2000;131:211–6.
22. Mandel L, Tharakan M. Treatment of unilateral masseteric hypertrophy with botulinum toxin: case report. J Oral MaxillofacSurg 1999;57:1017–19.
23. Rijsdijk BA, van ES RJ, Zonneveld FW, Steenks MH, Koole R. Botulinum toxin type A treatment
of cosmetically disturbing masseteric hypertrophy. Ned TijdschrGeneeskd 1998;142:529–32.
24. Kim HJ, Yum KW, Lee SS, Hea HS, Sea K. Effects of botulinum toxin A on bilateral masseteric hypertrophy evaluated by computed tomographic measurement. Dermatologic surgery 2003;29:484-9
25. Polo M. Botulinums type A (BOTOX) for the neuromuscular correction of excessive gingival display on smiling (gummy smile). Am J OrthodDentofacialOrthop 2008; 133:195-203.
26. Torres MA, Aytés LB, EscodaCG.Salivary gland application of botulinum toxin for the treatment of sialorrhea. Med Oral Patol Oral Cir Bucal2007;12:511-7
27. Shetty S, Dawes P, Ruske D, Al-qudah M, LyonsB,et al. Botulinum toxin type-A (Botox-A) injections for treatment of sialorrhoea in adults: a New Zealand study, NZMJ 2006;119:1240
28. Sibley D. Restoring the Edentulous Patient WithOromandibular Dystonia: Treatment Planning Considerations and a Review of the Current Literature.AaomsOctober 2013.Available from:https://aaoms.confex.com/aaoms/am1310/webprogram/Paper3664.html
29. Erdal J, Ostergaard L, Fuglsang-Frederiksen A, Werdelin L, Dalager T, Sjo O, et al. Experience with long-term botulinum toxin treatment of oromandibular dystonia, guided by quantitative EMG. MovDisord 1996;11(Suppl- Abstract P790):210.
30. Dr. G. Ko. How Botox works for the treatment of chronic pain. -[lastcited on 2009].Available from: http://www.drkoprp.com/pdfs/botox Info.pdf
31. Dolly O. Synaptic transmissions: inhibition of neurotransmitter release by botulinum toxins. Headache 2003;43:16-24. 32. Image Reference:Arnon SS, Schechter R, Inglesby TV, Henderson DA, Bartlett JG, Ascher MS, et al. Botulinum Toxin as a Biological Weapon: Medical and Public Health Management.JAMA, 2001;285:1059-70
2. US Food and Drug Administration. Early Communication about an Ongoing Safety Review of Botox and Botox Cosmetic (Botulinum toxin
Type A) and Myobloc (Botulinum toxin TypeB). February 2008.-[accessed12October2010] Availablefrom:http:/www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm070366.htm
3. US Food and Drug Administration (United States). Early Communication about an Ongoing Safety Review of Botox and Botox Cosmetic (Botulinum toxin Type A) and Myobloc (Botulinum toxin Type B).April,2009.-[accessed 1 December 2010] Availablefrom:http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm070366.htm
4. US Food and Drug Administration. Information for Healthcare Professionals: OnabotulinumtoxinA (marketed as Botox/Botox Cosmetic), AbobotulinumtoxinA (marketed as Dysport) and RimabotulinumtoxinB (marketed as Myobloc). August,2009.-[accessed 1 December2010]Availablefrom:www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforhealthcareprofessionals/ucm174949.htm
5. Katz H.Botulinum Toxins in Dentistry-The New Paradigm for Masticatory Muscle Hypertonicity. Singapore Dent J 2005;27:7–12
6. BOTOX (onabotulinumtoxinA) for injection, for intramuscular, intradetrusor, or intradermal use.InitialU.S.Approval:1989Availablefrom:http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=33d066a9-34ff-4a1a-b38b-d10983df3300 7. Rao, L. B., Sangur, R., & Pradeep, S. Application of Botulinum toxin Type A: An arsenal in dentistry.IJDR2011;22:440-5.
8. Brashear A. The botulinum toxins in the treatment of cervical dystonia. SeminNeurol 2001;21:85–90.
9. Ihde S. Prophylactic use of botulinum toxin in dental implantlogy. Cranio‑maxillofacial Implant Dir2007;2:3‑8. 10. Kumar, P., Khattar, A., Goel, R., & Kumar, A. Role of Botox in Efficient Muscle Relaxation and Treatment Outcome: An Overview.Annals of medical and health sciences research2013;3:131.
11. Glaros AG, Tabacchi KN, Glass EG. Effect of parafunctional clenching on TMD pain and hearing loss. J Orofac Pain 1998; 12:145–52.12. Malcmacher L. "Botulinum Toxin (Botox and Dysport) Use for Dental and Facial Pain Treatment."American Academy of Facial Esthetics. [accessed 2012 January]Availablefrom:http:/www.facialesthetics.org/esthetics/articles/botulinum_toxin_botox_and_dysport_use_for_dental_and_facial_pain_treatment.
13. Borodic GE, Acquadro MA. The use of botulinum toxin for the treatment of chronic facial pain. J Pain 2002;3:21- 27.
14. Naumann M, Albanese A, Heinen F, Molenaers G, Relja M. Safety and efficacy of Botulinum toxin type A follow- ing long-term use. Eur J Neurol 13 (suppl) 2006;4:35-40.
15. Song PC, Schwartz J, Blitzer A. The emerging role of botulinum toxin in the treatment of temporomandibular disorders [reviews]. Oral Dis 2007;13:253-60.
16. Freund B, Schwartz M, Symington JM. The use of botulinum toxin for the treatment of temporomandibular disorders: preliminary findings. J Oral MaxillofacSurg 1999;57:916–20.
17. Kurtoglu C, Gur OH, Kurkcu M, Sertdemir Y, Guler-Uysal F, Uysal H. Effect of botulinum toxin A in myofascial pain patients with or without functional disc displacement. J Oral MaxillofacSurg2008;66:1644-51
18. Silberstein S, Mathew N, Saper J, Jenkins S. Botulinum toxin type A as a migraine preventive treatment. For the BOTOX Migraine Clinical Research Group. Headache 2000;40:445-50.
19. Elcio JP. BOTOX injections relieve severe facial pain.-[last cited 2009]Available from: http://www.news-medical.net/news/2005/10/25/14010.aspx.
20. Lawrence R. BOTOX for Headache: Mechanism of Action. -[last cited 2009]Available from: http://www.headachedrugs.com.Migrainepage.formulation.net/…/botox-for-headache-mechanism-of-action-t 164.htm.
21. Tan EK, Jankovic J. Treating severe bruxism with botulinum toxin. J Am Dent Assoc 2000;131:211–6.
22. Mandel L, Tharakan M. Treatment of unilateral masseteric hypertrophy with botulinum toxin: case report. J Oral MaxillofacSurg 1999;57:1017–19.
23. Rijsdijk BA, van ES RJ, Zonneveld FW, Steenks MH, Koole R. Botulinum toxin type A treatment
of cosmetically disturbing masseteric hypertrophy. Ned TijdschrGeneeskd 1998;142:529–32.
24. Kim HJ, Yum KW, Lee SS, Hea HS, Sea K. Effects of botulinum toxin A on bilateral masseteric hypertrophy evaluated by computed tomographic measurement. Dermatologic surgery 2003;29:484-9
25. Polo M. Botulinums type A (BOTOX) for the neuromuscular correction of excessive gingival display on smiling (gummy smile). Am J OrthodDentofacialOrthop 2008; 133:195-203.
26. Torres MA, Aytés LB, EscodaCG.Salivary gland application of botulinum toxin for the treatment of sialorrhea. Med Oral Patol Oral Cir Bucal2007;12:511-7
27. Shetty S, Dawes P, Ruske D, Al-qudah M, LyonsB,et al. Botulinum toxin type-A (Botox-A) injections for treatment of sialorrhoea in adults: a New Zealand study, NZMJ 2006;119:1240
28. Sibley D. Restoring the Edentulous Patient WithOromandibular Dystonia: Treatment Planning Considerations and a Review of the Current Literature.AaomsOctober 2013.Available from:https://aaoms.confex.com/aaoms/am1310/webprogram/Paper3664.html
29. Erdal J, Ostergaard L, Fuglsang-Frederiksen A, Werdelin L, Dalager T, Sjo O, et al. Experience with long-term botulinum toxin treatment of oromandibular dystonia, guided by quantitative EMG. MovDisord 1996;11(Suppl- Abstract P790):210.
30. Dr. G. Ko. How Botox works for the treatment of chronic pain. -[lastcited on 2009].Available from: http://www.drkoprp.com/pdfs/botox Info.pdf
31. Dolly O. Synaptic transmissions: inhibition of neurotransmitter release by botulinum toxins. Headache 2003;43:16-24. 32. Image Reference:Arnon SS, Schechter R, Inglesby TV, Henderson DA, Bartlett JG, Ascher MS, et al. Botulinum Toxin as a Biological Weapon: Medical and Public Health Management.JAMA, 2001;285:1059-70
Downloads
Published
201-01-04
How to Cite
Shah, S., Patel, V., Panchal, A., Mehta, H., & BhaumikNanavati, D. Botulinum Toxin – The New Paradigm A Review Articl: Botulinum Toxin – The New Paradigm. National Journal of Integrated Research in Medicine, 5(3), 127–133. https://doi.org/10.70284/njirm.v5i3.749
Issue
Section
Review Article
